Three separate data streams are now pointing the same direction on D.R. Horton. Short interest jumped, options hedging held elevated, and the cost to borrow ticked higher — all within the same week that the stock fell 1.8%.
The month-long retreat in short positioning has ended abruptly. SI hit 4.1% of free float on July 24, up 11.5% in a single day and 11.0% on the week. That reversal is notable given the prior trend: short interest had fallen roughly 6.4% over the past month as sellers covered into — and after — the Q3 earnings release. The fresh build suggests the post-earnings covering is done and new short positions are being established at current levels.
Days-to-cover stands at 5.69 per the most recent FINRA fortnightly data, meaning any sustained squeeze would take time to resolve.
The put/call ratio of 1.25 remains well above its 20-day mean of 0.97. That is 1.5 standard deviations elevated — less extreme than the 3+ sigma readings seen in the days immediately around the July 21 earnings release, but still consistent with a market that has not let its guard down. Previous coverage noted the PCR surging past 1.36 as the stock fell despite the earnings beat; it has since eased modestly but hasn't returned to the sub-0.87 readings that prevailed through most of June and early July. Downside hedging demand has settled at a structurally higher level than the pre-earnings baseline.
Cost to borrow has climbed from 0.30% on July 15 to 0.46% mid-week, a 53% rise in one week — though at 0.34% as of July 24, it remains in historically low territory. More importantly, availability is extraordinarily loose at 4,569%. That figure means roughly 46 shares sit available to borrow for every one currently lent out. There is no borrow squeeze anywhere in sight. Shorts are paying marginally more to maintain positions, but finding the shares is not the constraint.
Post-earnings analyst action split cleanly. Keefe Bruyette & Woods cut its target from $175 to $167 while keeping a Market Perform rating. Evercore ISI moved the opposite direction, raising its target from $171 to $177. RBC Capital's Underperform rating with a $125 target sits well below a consensus mean of $164.17 — a $17 premium to the $146.76 closing price on July 24. Capital Research & Management added 3.7 million shares as of June 30, the largest institutional change in the top-15 holder list.
See the live data behind this article on ORTEX.
Open DHI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
